1. Home
  2. LEE vs SCLX Comparison

LEE vs SCLX Comparison

Compare LEE & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEE
  • SCLX
  • Stock Information
  • Founded
  • LEE 1890
  • SCLX 2011
  • Country
  • LEE United States
  • SCLX United States
  • Employees
  • LEE N/A
  • SCLX N/A
  • Industry
  • LEE Newspapers/Magazines
  • SCLX Biotechnology: Pharmaceutical Preparations
  • Sector
  • LEE Consumer Discretionary
  • SCLX Health Care
  • Exchange
  • LEE Nasdaq
  • SCLX Nasdaq
  • Market Cap
  • LEE 38.2M
  • SCLX 33.9M
  • IPO Year
  • LEE N/A
  • SCLX N/A
  • Fundamental
  • Price
  • LEE $6.38
  • SCLX $6.16
  • Analyst Decision
  • LEE
  • SCLX Strong Buy
  • Analyst Count
  • LEE 0
  • SCLX 3
  • Target Price
  • LEE N/A
  • SCLX $367.50
  • AVG Volume (30 Days)
  • LEE 35.4K
  • SCLX 113.0K
  • Earning Date
  • LEE 07-31-2025
  • SCLX 08-12-2025
  • Dividend Yield
  • LEE N/A
  • SCLX N/A
  • EPS Growth
  • LEE N/A
  • SCLX N/A
  • EPS
  • LEE N/A
  • SCLX N/A
  • Revenue
  • LEE $591,094,000.00
  • SCLX $50,710,000.00
  • Revenue This Year
  • LEE N/A
  • SCLX $107.00
  • Revenue Next Year
  • LEE N/A
  • SCLX $82.52
  • P/E Ratio
  • LEE N/A
  • SCLX N/A
  • Revenue Growth
  • LEE N/A
  • SCLX 7.79
  • 52 Week Low
  • LEE $5.83
  • SCLX $3.60
  • 52 Week High
  • LEE $19.63
  • SCLX $78.05
  • Technical
  • Relative Strength Index (RSI)
  • LEE 44.10
  • SCLX 61.16
  • Support Level
  • LEE $6.04
  • SCLX $5.72
  • Resistance Level
  • LEE $6.78
  • SCLX $6.39
  • Average True Range (ATR)
  • LEE 0.43
  • SCLX 0.42
  • MACD
  • LEE 0.05
  • SCLX 0.13
  • Stochastic Oscillator
  • LEE 47.01
  • SCLX 94.23

About LEE Lee Enterprises Incorporated

Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: